Standard Dosage for Nivolumab in Adults
Nivolumab (Opdivo) is typically dosed at 3 mg/kg intravenously every 2 weeks or 240 mg every 2 weeks for adults with solid tumors like melanoma, non-small cell lung cancer, or renal cell carcinoma. For certain indications such as classical Hodgkin lymphoma, it's 240 mg every 2 weeks. Flat dosing of 480 mg every 4 weeks is also approved as an alternative in many cases, reducing the need for weight-based calculations.[1][2]
How Weight-Based Dosing Is Calculated
Calculate the dose by multiplying the patient's actual body weight in kilograms by 3 mg/kg. For example:
- A 70 kg adult receives 210 mg (3 × 70) every 2 weeks.
Administer over 30 minutes. Use actual body weight unless obese; no specific adjustments for BMI are mandated, but clinicians may cap at ideal body weight in some protocols.[1][3]
Dosage by Cancer Type
| Indication | Weight-Based Dose | Flat Dose Option | Frequency |
|------------|-------------------|------------------|-----------|
| Melanoma (monotherapy) | 3 mg/kg | 240 mg or 480 mg | Every 2 or 4 weeks |
| NSCLC (after platinum chemo) | 3 mg/kg | 240 mg | Every 2 weeks |
| Renal cell carcinoma | 3 mg/kg + ipilimumab induction, then monotherapy | 240 mg | Every 2 weeks |
| Hodgkin lymphoma | - | 240 mg | Every 2 weeks |
Doses adjust lower with combination therapies (e.g., 1 mg/kg nivolumab + 3 mg/kg ipilimumab every 3 weeks for melanoma).[1][2]
Differences Between Weight-Based and Flat Dosing
Weight-based (mg/kg) was the original approach for precision across body sizes but requires individual calculations. FDA approved flat doses (240 mg Q2W or 480 mg Q4W) in 2018-2020 for most indications after trials showed equivalent exposure and efficacy, simplifying administration. Flat dosing is now preferred in practice to minimize errors.[3][4]
Adjustments for Special Populations
- Renal/hepatic impairment: No dose changes needed for mild-moderate cases; monitor closely.
- Elderly: Same as adults; no routine reduction.
- Obesity: Use actual body weight; studies confirm safety up to 120 kg.
- Pediatrics: Higher, often 3-15 mg/kg based on age/weight, but not for adults.[1][2]
Common Reasons for Dose Changes
Hold for grade 2+ immune-related adverse events (e.g., colitis, pneumonitis); resume at same dose upon recovery. Permanently discontinue for grade 3-4 toxicity or recurrent issues. No standard reductions—it's hold or stop.[1]
[1]: Opdivo Prescribing Information (Bristol Myers Squibb, 2023)
[2]: FDA Label for Nivolumab
[3]: ASCO Guidelines on Immunotherapy Dosing
[4]: DrugPatentWatch.com - Nivolumab Patents and Exclusivity